Global CIS Insulin Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In June 2024, Eli Lilly and Company (NYSE: LLY) revealed intricate findings from SYNERGY-NASH, a phase 2 trial involving 190 participants, with or without type 2 diabetes, investigating the potential use of tirzepatide in adults diagnosed with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis.

• In May 2024, Novo Nordisk released the results of the FRONTIER 2 trial, a 26-week, open-label, randomized, and multicenter study involving 254 participants aged 12 years and above with haemophilia A, with or without inhibitors. The trial compared the effectiveness and safety of weekly and monthly subcutaneous injections of Mim8 to no preventive treatment and previous use of coagulation factor prophylaxis.

The Global CIS Insulin Market can be analyzed through segmentation based on product type, end-user, and region, offering insights into the diverse facets of insulin pump technology adoption and utilization worldwide. Firstly, segmentation by product type distinguishes between different categories of CIS devices, including traditional insulin pumps and hybrid closed-loop systems. Traditional insulin pumps deliver basal and bolus insulin doses through continuous subcutaneous infusion, allowing users to manually adjust insulin doses based on glucose levels and meal consumption. On the other hand, hybrid closed-loop systems, also known as artificial pancreas systems, combine insulin pump technology with continuous glucose monitoring (CGM) to automate insulin delivery and maintain glucose levels within target ranges. This segmentation highlights the evolution of CIS technology from standalone insulin pumps to integrated systems that offer greater automation and control over insulin therapy.

Segmentation by end-user identifies the various stakeholders involved in the adoption and utilization of CIS devices, including patients, healthcare providers, and diabetes care centers. Patients with type 1 diabetes, who rely on exogenous insulin for glycemic control, represent the primary end-users of CIS devices, benefiting from continuous insulin delivery, real-time glucose monitoring, and personalized insulin dosing. Healthcare providers, including endocrinologists, diabetes educators, and primary care physicians, play a crucial role in prescribing, managing, and monitoring CIS therapy, guiding patients in optimizing insulin dosing and carbohydrate management. Diabetes care centers, such as specialized clinics and hospitals, serve as essential hubs for CIS initiation, training, and ongoing support, providing comprehensive care and education to patients and caregivers on device operation, glucose monitoring, and diabetes self-management.

Segmentation by region provides insights into the geographical distribution of CIS device adoption and market dynamics across different global markets. North America and Europe are prominent regions in the Global CIS Insulin Market, characterized by high awareness, reimbursement coverage, and adoption rates of CIS technology. These regions benefit from well-established healthcare infrastructure, regulatory frameworks, and patient advocacy initiatives that support the integration of CIS devices into diabetes management protocols. In contrast, emerging markets in Asia Pacific, Latin America, and the Middle East and Africa exhibit growing demand for CIS devices driven by increasing diabetes prevalence, rising disposable incomes, and expanding access to healthcare services. As manufacturers expand their presence and distribution networks in these regions, the Global CIS Insulin Market is poised for continued growth and innovation, addressing unmet needs and improving diabetes care on a global scale.

Global CIS Insulin Segment Analysis

In this report, the Global CIS Insulin Market has been segmented by Product Type, Source Type, Application and Geography.

Global CIS Insulin Market, Segmentation by Product Type

The Global CIS Insulin Market has been segmented by Product Type into Rapid Acting Analog, Short Acting Insulin, Intermediate Acting Insulin, Long Acting Analog and Pre-Mixed.

The rapid-acting analog insulins, characterized by their rapid onset of action and short duration, are commonly used for mealtime bolus dosing in CIS devices. These insulins mimic the physiological insulin response to food intake, enabling users to adjust insulin doses according to carbohydrate content and glycemic load, thereby optimizing postprandial glucose control and minimizing hyperglycemia risk. Short-acting insulins, with a slightly slower onset and longer duration compared to rapid-acting analogs, are utilized for basal insulin infusion in CIS systems, providing a steady supply of insulin between meals and overnight to maintain stable blood glucose levels.

Intermediate-acting insulins offer an intermediate duration of action, providing basal insulin coverage for longer durations compared to short-acting insulins. These insulins are often used in CIS devices to supplement rapid-acting or short-acting bolus insulin doses, ensuring continuous insulin delivery throughout the day and overnight. Long-acting analog insulins, characterized by their extended duration of action and peakless profiles, are employed for basal insulin infusion in CIS systems, delivering a steady and consistent supply of insulin over 24 hours to mimic physiological basal insulin secretion. Pre-mixed insulin formulations, which combine rapid-acting or short-acting insulin with intermediate-acting insulin in fixed ratios, offer convenience and simplicity in CIS therapy, providing both basal and bolus insulin coverage in a single formulation for users who prefer a simplified dosing regimen.

This segmentation reflects the versatility and customization options available within the Global CIS Insulin Market, allowing healthcare providers and patients to tailor insulin therapy to individual needs, preferences, and lifestyle factors. By offering a range of insulin formulations suitable for basal and bolus insulin delivery in CIS devices, manufacturers address the diverse requirements of diabetic patients with varying insulin sensitivities, glycemic targets, and meal patterns. Ongoing research and development efforts aim to further refine insulin formulations, improve insulin stability, and enhance insulin delivery mechanisms in CIS devices, fostering innovation and advancement in diabetes care on a global scale.

Global CIS Insulin Market, Segmentation by Source Type

The Global CIS Insulin Market has been segmented by Source Type into Insulin Analogs and Human Recombinant Insulin.

The insulin analogs are synthetic insulins engineered to mimic the physiological action of endogenous insulin more closely than traditional human recombinant insulin. These analogs offer several advantages over human insulin, including faster onset of action, more predictable pharmacokinetics, and reduced risk of hypoglycemia. As a result, insulin analogs have gained widespread acceptance and are commonly prescribed for the management of diabetes in the CIS region and globally. With ongoing research and development efforts, new generations of insulin analogs continue to emerge, offering improved efficacy, safety, and convenience for patients with diabetes.

Human recombinant insulin, derived from genetically engineered bacteria or yeast cells, represents another important segment in the CIS Insulin Market. Despite the advent of insulin analogs, human recombinant insulin remains a staple therapy for many patients with diabetes, particularly in resource-constrained settings where cost considerations may influence treatment choices. Human insulin is available in various formulations, including rapid-acting, short-acting, intermediate-acting, and long-acting formulations, providing flexibility in insulin regimen customization to meet individual patient needs. While human insulin may have a slightly slower onset of action and a higher risk of hypoglycemia compared to insulin analogs, it remains an essential treatment option for patients with diabetes in the CIS region.

The segmentation of the CIS Insulin Market into insulin analogs and human recombinant insulin reflects the diversity of therapeutic options available for managing diabetes in the region. Healthcare providers consider various factors, including patient preferences, treatment goals, and cost considerations, when selecting insulin therapies for individuals with diabetes. While insulin analogs offer several advantages in terms of efficacy and safety, human recombinant insulin remains a viable and cost-effective treatment option for many patients. By offering a range of insulin products tailored to the needs of diverse patient populations, the CIS Insulin Market strives to optimize diabetes management outcomes and improve the quality of life for individuals living with diabetes in the region.

Global CIS Insulin Market, Segmentation by Application

The Global CIS Insulin Market has been segmented by Application into Type I & Other Diabetes and Type II Diabetes.

The Type I diabetes, characterized by autoimmune destruction of pancreatic beta cells and absolute insulin deficiency, necessitates lifelong insulin therapy for glycemic control. CIS devices play a critical role in Type I diabetes management by providing continuous subcutaneous insulin infusion, mimicking physiological insulin secretion, and offering flexibility in insulin dosing and delivery. These devices enable Type I diabetes patients to achieve tighter glycemic control, reduce hypoglycemia risk, and enhance quality of life compared to multiple daily injections (MDI) or conventional insulin regimens. CIS technology integration with continuous glucose monitoring (CGM) systems allows real-time glucose monitoring and automated insulin adjustment, offering personalized and proactive diabetes management for Type I diabetes patients.

In contrast, Type II diabetes, characterized by insulin resistance and relative insulin deficiency, often requires a multifaceted approach to glycemic management, including lifestyle modifications, oral antidiabetic medications, and injectable therapies such as insulin. While Type II diabetes patients typically begin with oral antidiabetic agents to improve insulin sensitivity and reduce hepatic glucose production, progressive disease may necessitate insulin initiation to achieve glycemic targets. CIS insulin pumps offer an alternative insulin delivery option for Type II diabetes patients who require intensive insulin therapy or have failed to achieve glycemic control with oral medications or injectable therapies. By providing precise and customizable insulin dosing, CIS devices enable Type II diabetes patients to optimize glycemic management, reduce hyperglycemia excursions, and improve metabolic outcomes, thereby enhancing overall diabetes care and patient satisfaction.

The segmentation of the Global CIS Insulin Market by application into Type I & Other Diabetes and Type II Diabetes underscores the importance of personalized diabetes management and tailored treatment strategies for different patient populations. While Type I diabetes patients rely on CIS devices as a primary means of insulin delivery to maintain glycemic control, Type II diabetes patients may benefit from CIS technology as an adjunctive therapy option to oral antidiabetic medications or injectable therapies. As the prevalence of diabetes continues to rise globally, fueled by factors such as aging populations, urbanization, and sedentary lifestyles, the Global CIS Insulin Market plays a crucial role in meeting the evolving needs of diabetic patients and advancing diabetes care through innovative and patient-centric solutions.

Global CIS Insulin Market, Segmentation by Geography

In this report, the Global CIS Insulin Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global CIS Insulin Market Share (%), by Geographical Region, 2024

North America holds a prominent position in the market, driven by factors such as a high prevalence of diabetes, advanced healthcare infrastructure, and widespread adoption of insulin pump therapy. With a significant portion of the population affected by diabetes, North American countries prioritize the management of diabetes through continuous subcutaneous insulin delivery systems. The region's strong regulatory frameworks and reimbursement policies support the adoption of innovative insulin delivery technologies, driving market growth for CIS devices and accessories.

Europe closely follows North America in the CIS Insulin Market, benefiting from its well-established healthcare systems, robust research and development infrastructure, and emphasis on personalized diabetes care. European countries prioritize the use of CIS systems as part of comprehensive diabetes management strategies, aiming to improve glycemic control, enhance patient quality of life, and reduce the risk of diabetes-related complications. The region's collaborative research networks and partnerships between academia, industry, and healthcare providers foster innovation in CIS technology and applications, driving market expansion across diverse therapeutic areas. Europe's aging population and increasing prevalence of diabetes underscore the importance of effective insulin delivery solutions, further fueling demand for CIS devices and accessories.

In the Asia Pacific region, the CIS Insulin Market shows promising growth prospects, propelled by increasing healthcare expenditures, rising prevalence of diabetes, and expanding access to diabetes care services. Countries such as China, India, and Japan are witnessing a surge in demand for CIS systems as part of comprehensive diabetes management programs. With the adoption of advanced insulin delivery technologies and a growing emphasis on patient-centered care, healthcare providers in the Asia Pacific region are increasingly incorporating CIS into routine clinical practice to optimize glycemic control and improve patient outcomes. Collaborations between international diabetes organizations and local stakeholders contribute to the development and implementation of CIS solutions tailored to the needs of diverse populations across the Asia Pacific region.

This report provides an in depth analysis of various factors that impact the dynamics of Global CIS Insulin Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Continuous Monitoring
• Precision Delivery

• Improved Control : Improved control is a paramount objective within the Global CIS Insulin Market, reflecting the ongoing pursuit of enhanced glycemic management, reduced hypoglycemia risk, and improved quality of life for individuals with diabetes. Continuous Insulin Infusion Systems (CIS) have emerged as a pivotal tool in achieving these goals by offering precise and customizable insulin delivery, real-time glucose monitoring, and proactive management of glycemic fluctuations. By providing continuous subcutaneous insulin infusion and integrating with continuous glucose monitoring (CGM) technology, CIS devices enable patients to maintain tighter glycemic control and minimize glycemic variability compared to conventional insulin regimens. This improved glycemic control translates into reduced hemoglobin A1c (HbA1c) levels, fewer hyperglycemic and hypoglycemic episodes, and better long-term health outcomes for diabetes patients.

  One of the key factors driving improved control within the Global CIS Insulin Market is the integration of advanced technologies and smart algorithms into CIS devices, enabling personalized and proactive diabetes management. Hybrid closed-loop systems, also known as artificial pancreas systems, exemplify this innovation by combining insulin pump technology with predictive algorithms and automated insulin adjustment algorithms. These systems continuously monitor glucose levels and adjust insulin delivery in real time based on predictive trends, meal consumption, physical activity, and other physiological parameters, optimizing glycemic control while minimizing the risk of hypoglycemia. Additionally, user-friendly interfaces, smartphone connectivity, and remote monitoring capabilities enhance patient engagement, adherence, and satisfaction with CIS therapy, fostering long-term success in diabetes management.

  The continuous evolution and refinement of CIS technology, coupled with ongoing research and development efforts, are driving further improvements in glycemic control and patient outcomes within the Global CIS Insulin Market. Manufacturers are investing in the development of next-generation CIS devices with advanced features such as closed-loop insulin delivery, artificial intelligence algorithms, customizable insulin dosing algorithms, and predictive analytics for glucose forecasting. These innovations aim to address unmet needs in diabetes care, such as nocturnal hypoglycemia prevention, exercise-related glucose management, and personalized insulin dosing optimization. By harnessing the power of technology and innovation, the Global CIS Insulin Market is poised to revolutionize diabetes management, empowering patients to achieve better glycemic control, minimize diabetes-related complications, and improve overall quality of life.

Restraints

• Regulatory Compliance
• Device Complexity

• Cost Concerns : Cost concerns are significant considerations in the Global CIS (Continuous Subcutaneous Insulin) Market, affecting both healthcare providers and patients. While CIS offers benefits such as improved glycemic control, reduced risk of hypoglycemia, and enhanced quality of life for individuals with diabetes, the initial investment and ongoing expenses associated with insulin pump therapy can be substantial. Healthcare providers must consider the upfront costs of purchasing CIS devices, infusion sets, and insulin reservoirs, as well as the expenses related to training patients and healthcare professionals on device usage and maintenance. Ongoing costs such as consumables, insulin supplies, and device upgrades contribute to the overall cost of CIS therapy, posing financial challenges for healthcare systems and patients alike.

  For patients with diabetes, affordability and accessibility of CIS therapy are significant concerns, particularly in regions with limited insurance coverage or out-of-pocket payment models. The high cost of CIS devices and supplies may present barriers to adoption and adherence for individuals with limited financial resources or inadequate insurance coverage. Disparities in access to healthcare services and socioeconomic factors, such as income level and employment status, may exacerbate cost concerns and contribute to inequalities in diabetes management outcomes. Patients may face difficult choices between managing the costs of diabetes care and meeting other essential needs, potentially compromising their health and well-being.

  Addressing cost concerns in the Global CIS Insulin Market requires collaborative efforts from stakeholders across the healthcare ecosystem, including manufacturers, policymakers, payers, and advocacy organizations. Manufacturers can explore strategies to reduce the production costs of CIS devices and accessories, streamline supply chains, and optimize manufacturing processes to make CIS therapy more affordable and accessible for patients. Policymakers and payers play a crucial role in developing reimbursement policies, insurance coverage schemes, and patient assistance programs to alleviate financial burdens associated with CIS therapy and ensure equitable access to diabetes care. Healthcare providers can implement cost-effective diabetes management strategies, such as value-based care models, patient education programs, and integrated care pathways, to optimize resource utilization and improve the affordability of CIS therapy for patients with diabetes.

Opportunities

• Patient Empowerment
• Improved Outcomes

• Integration Solutions : Integration solutions are a pivotal component of the Global CIS Insulin Market, facilitating seamless interoperability between Continuous Insulin Infusion Systems (CIS) and other diabetes management technologies. These solutions enable the integration of CIS devices with complementary technologies such as continuous glucose monitoring (CGM) systems, insulin dose calculators, smartphone apps, and cloud-based platforms, creating an interconnected ecosystem for diabetes care. By integrating CIS devices with CGM systems, patients gain real-time insights into their glucose levels, enabling proactive adjustments to insulin dosing and reducing the risk of hypo- and hyperglycemic events. Moreover, integration solutions can automate insulin delivery algorithms based on CGM data, optimizing glycemic control and minimizing the burden of diabetes management for patients.

  Integration solutions also play a crucial role in enhancing patient engagement and empowerment by providing access to actionable insights, personalized recommendations, and remote monitoring capabilities. Through smartphone apps and web-based platforms, patients can track their glucose levels, insulin doses, carbohydrate intake, physical activity, and other relevant metrics in real-time, empowering them to make informed decisions about their diabetes management. Healthcare providers can remotely monitor patients' data, identify trends, and intervene proactively to optimize insulin therapy, address adherence issues, and prevent diabetes-related complications. Integration solutions facilitate communication and data sharing between patients and healthcare providers, enabling collaborative decision-making and personalized care planning to improve diabetes outcomes.

  Integration solutions drive innovation and differentiation in the Global CIS Insulin Market by enabling the development of advanced features and functionalities that enhance user experience, treatment efficacy, and device interoperability. Manufacturers leverage integration solutions to incorporate artificial intelligence (AI), machine learning algorithms, predictive analytics, and decision support tools into CIS devices and companion apps, offering personalized insulin dosing recommendations, adaptive insulin delivery algorithms, and predictive alerts for impending hypoglycemia or hyperglycemia events. Integration with electronic health record (EHR) systems, telemedicine platforms, and wearable technologies further expands the utility and accessibility of CIS devices, enabling seamless data exchange, remote consultations, and holistic diabetes management across care settings. As integration solutions continue to evolve and mature, the Global CIS Insulin Market is poised to witness continued growth and innovation, driving improvements in diabetes care and patient outcomes on a global scale.

Key players in Global CIS Insulin Market include:

• Bristol-Myers Squibb
• Novartis
• Takeda Pharmaceuticals
• Boehringer Ingelheim
• Biocon
• Dongbao Enterprise Group Co. Ltd.
• Merck KGaA
• Oramed Pharmaceuticals Inc.
• Halozyme Therapeutics
• Wanbang Biopharma
• Xinbai Pharmaceutical

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis